Alcon Inc., CH0432492467

Alcon stock faces a lower Jefferies target after Q2 growth broke through? No question allowed

Published on 10/03/2026 at 22:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock finished at CHF 52.84 on October 2, 2026, while Jefferies cut its target to USD 85 from USD 95. Q2 sales rose 8 percent to USD 2.78 billion.

Flat lay product photography on white marble. Contact lens case, lens solution bottle, soaking dish, and optometry trial lens kit arranged neatly with soft studio overhead lighting, clinical cleanliness, no text on items
Alcon CH0432492467: Flatlay mit Kontaktlinsenbehälter, Pflegelösung und Probierlinsen Set auf weißem Marmor, Illustration mit AI erstellt.

Alcon stock (ISIN CH0432492467) finished at CHF 52.84 on SIX on October 2, 2026, with a daily change of -0.04 percent. The immediate valuation debate centers on Jefferies, which cut its price target to USD 85 from USD 95 on September 22, 2026, while keeping a Buy rating, according to Markets Insider.

Jefferies cuts target to USD 85

The revised target reflects pressure across ophthalmology, including macroeconomic and competitive concerns cited by Jefferies analyst Michael Sarcone. The change leaves the bank's rating unchanged but reduces the target by USD 10, a 10.5 percent cut from USD 95.

For the Swiss-listed shares, the key market reference is CHF 52.84, with a session low of CHF 52.62, a high of CHF 53.46 and volume of 815,830 shares on October 2, 2026. That range shows a contained session, while the target revision provides a clearer risk signal than the day's small percentage move.

Q2 revenue reaches USD 2.78 billion

Alcon's second-quarter 2026 net sales rose 8 percent year over year to USD 2.78 billion, and core EPS reached USD 0.84, up 10.5 percent, according to The Globe and Mail. Core EPS also exceeded the consensus estimate by 9.09 percent, giving the earnings profile a quantified counterweight to the lower target.

Surgical sales rose 8 percent to USD 1.57 billion, while Vision Care sales increased 8 percent to USD 1.21 billion. Alcon maintained its 2026 constant-currency sales growth outlook of 5 percent to 7 percent and lifted core diluted EPS growth guidance to 12 percent to 15 percent from 10 percent to 13 percent, the same report said.

Next results set for November

Alcon's next earnings report is scheduled for November 10, 2026, according to GetSignal. That date gives investors a defined checkpoint for judging whether product launches and margin improvements can offset the competitive pressure cited in the Jefferies update.

Alcon stock trades at CHF 52.84

Alcon stock had an official closing price of CHF 52.84 on SIX on October 2, 2026. The listing is identified as ALC on SIX under ISIN CH0432492467 by Global Banking and Finance.

Alcon stock facts

  • Company: Alcon Inc.
  • ISIN: CH0432492467
  • Ticker: ALC
  • Trading venue: SIX
  • Closing price (October 2, 2026): CHF 52.84
  • Sector / Industry: Healthcare / Medical Specialties

More news and analyses on Alcon stock

Disclaimer...

en | CH0432492467 | ALCON INC. | boerse | 70221721 | bgmi